NVE Corp. puts a new spin on sensors; Organovo creates human tissues. Read More
Benjamin Shepherd is a recognized exchange-traded fund (ETF), mutual fund and stock expert with an extensive background analyzing time-tested funds, including their managers and strategies. Ben looks for investments that have proven themselves in both bull and bear markets. Ben also specializes in covering emerging markets, pinpointing the most dynamic investments in developing nations for market-beating growth.
Ben is an analyst for Global Income Edge and regularly contributes to Personal Finance, Investing Daily’s flagship product.
Analyst Articles
One exploding battery (well, closer to a dozen) has been dragging down semiconductor stocks. Read More
Bankers have been in the hot seat thanks to a wave of scandals, ushering in the departure of Wells Fargo’s (NYSE: WFC) CEO and driving Deutsche Bank’s (NYSE: DB) share price below even financial crisis levels. On top of that, while revenue and earnings at most of the major banks… Read More
While no single step Tremble has taken will have a huge impact on its performance, in sum they will help boost its margins and profitability going forward, especially as it launches new products that are a better fit with its business. Read More
Sometimes all it takes is a rumor to get a stock moving, especially if people like what they hear. Read More
Shares of Paycom Software (NYSE: PAYC) have made a decent jump over the past week, with a five-day gain of 7% after a few favorable developments.Despite it’s nearly $3 billion market cap, Paycom is still something of an upstart in the industry, facing off against major competitors like $23 billion… Read More
Just over 11.3 million people watched last night’s 68th Primetime Emmy Awards, the television industry’s confab to honor excellence in the field. In a ceremony similar to the Academy Awards, dozens of awards are doled out honoring writers, directors and actors in everything from documentaries to comedy series. There was… Read More
Not only does terrorism take a human toll, it has a real economic impact. Read More
Here are three hidden gems analysts have overlooked—for now. Read More
We may be living in the “Year of the Mega Deal,” but the latest announced merger may signal an era is coming to an end.Bayer’s (OTC: BAYRY) proposed takeover of Monsanto (NYSE: MON), is a transaction valued at $66 billion including debt, making it the biggest deal of the year… Read More